Home parenteral nutrition (HPN) and home intravenous (IV) hydration are complex, high-risk life-sustaining therapies for children and adults with severe digestive disorders. HPN compounding errors have the potential to cause serious patient harm. Here we present a retrospective case series at an interdisciplinary pediatric HPN program that includes specialized pharmacists reconciling prescriptions against commercial compounding records. Seven HPN or IV hydration patients were affected by significant errors in anion balance, copper, potassium, sodium, and infusion volume. Outpatient pharmacists' or other clinicians' review of compounding records as part of routine quality assurance process is critical for identifying and preventing errors. (Nutr Clin Pract. 2017;32:820-825) 
Parenteral nutrition (PN) is a complex intravenous (IV) nutrition admixture that contains 15 or more individual components, including dextrose, amino acids, electrolytes, trace elements, and vitamins, that are combined using sterile technique. This high-risk, life-sustaining therapy may be prescribed for use by patients in the home setting. Use of home PN (HPN) has increased among children, as medical advances have improved survival of children with primary digestive disorders that result in intestinal failure. 1 Although premixed PN solutions are available commercially, these solutions are often not ideal for pediatric use, especially for those patients with chronic gastrointestinal (GI) conditions, because of the high variability of their nutrition and hydration needs. 2 Over 1500 commercial home infusion pharmacies exist in the United States to compound customized HPN. 3 Due to consolidation within the industry, many large commercial home infusion pharmacy companies now operate local branches nationwide. While there are published guidelines available, there are currently no standardized methods for prescribing or compounding HPN. [4] [5] [6] [7] Errors in PN compounding have the potential to cause serious patient harm. 8, 9 While PN compounding errors in the inpatient setting have been well documented, there are limited data regarding HPN errors compounded by home infusion pharmacies. 8, 10 In our previous 4-month pilot study, we reported a 46% rate of discrepancies between HPN prescriptions and composition among pediatric outpatients during a 4-month pilot period. 11 We aim to describe our experience with pediatric HPN patients in the outpatient setting affected by compounding errors to better appreciate underlying causes of common errors that may inform future safety initiatives.
Methods
The Home Parenteral Nutrition Program at our institution is an interdisciplinary program with a team of HPN specialists, including pediatric gastroenterology, registered dietitians, nursing, and pharmacy. The HPN team follows patients during both outpatient visits and inpatient admissions and adjusts HPN prescriptions as
needed. Prior to routine ambulatory encounters, home infusion companies are contacted by our program coordinator and asked to provide the most recent compounding records for each scheduled patient's HPN to the team. These compounding records show the exact amounts of each ingredient used to make the HPN solution. Pharmacists specialized in nutrition support review the HPN compounding records and compare these records with the current HPN prescription to assess for accuracy. Currently, this occurs with solutions that have been already compounded and are in use by the patients. Similarly, the pharmacists also review compounding records for any IV hydration solutions prescribed for patients who have been weaned from PN support. IV hydration solutions may contain only dextrose and electrolytes, not amino acids. The HPN pharmacists report any discrepancies found to the rest of the team and to the home infusion pharmacy. The team plans interventions based on the nature of the discrepancy and the patient's clinical status. Any discrepancies that result in a change in therapy or require additional monitoring are discussed with the family. The HPN pharmacists also collaborate with the team during inpatient admissions to ensure continuity of care. Here we report our experience with 7 pediatric patients affected by significant compounding errors in their HPN or IV hydration. The errors occurred from April 2011 through November 2015. During this time period, > 216 distinct patients were followed by our institution's HPN clinic (database began October 2011). The findings are summarized in Table 1 . This work did not require institutional review board approval, since it was consistent with our institution's definition of quality improvement.
Case 1
A 2-year-old female with short bowel syndrome secondary to neonatal midgut volvulus and malrotation developed acute agitation, headaches, and vomiting after starting infusion of newly delivered IV hydration. In the emergency department the following morning, her laboratory studies were notable for glucose (370 mg/dL; normal range, 61-100 mg/dL) and sodium (176 mmol/L; normal range, 135-148 mmol/L). Head computed tomography (CT) showed 2 intraparenchymal hemorrhages, a new finding in this patient, which were attributed to hypernatremic dehydration. The national home infusion pharmacy was contacted, who then referred the team to a different local pharmacy that had been subcontracted to prepare the first doses of this hydration solution. At the time of the event, the HPN team was not aware that a secondary pharmacy was being used. The HPN pharmacist then contacted the pharmacy where IV hydration had been prepared and uncovered a 10-fold increase in the sodium content (770 mEq/L compounded vs 77 mEq/L as prescribed). Inpatient laboratory testing of the home IV hydration provided by the family confirmed the compounding error. Unfortunately, a root cause analysis was not available for review. Over the first 36 hours of hospitalization, the patient's sodium was gradually normalized. The patient was discharged home after 3 days at near-baseline neurologic status, with no lasting effects. The national homecare company no longer uses a secondary pharmacy and established a local branch, thereby overseeing all compounding.
Case 2
A 6-month-old female with history of intrauterine meconium pseudo-cyst leading to short bowel syndrome was discharged on HPN following a prolonged hospitalization. The patient's home infusion pharmacy contacted her mother to report that the PN bags they had delivered to the patient's home the day prior were made incorrectly with sodium 10% higher and potassium 5% lower than prescribed. The home infusion pharmacy also told the mother that they would be compounding a new, corrected shipment of HPN for same-day delivery. The patient's mother alerted the HPN team about the error. The patient was asymptomatic, and PN therapy continued without interruption once the new delivery was made. A root cause analysis of the compounding error revealed that the home infusion pharmacist had been doing calculations using a spreadsheet, unaware of a proprietary software program that was available for their PN automated compounding device (ACD). The spreadsheet was known to have limitations when balancing electrolyte salt amounts in the solution, so some calculations were still being done by hand. Although the company had double-checks of calculations in place, the error was not recognized prior to dispensing of the HPN bags. The pharmacy did not disclose a reason for the delay in error discovery. The specific company branch that compounded this solution also reported having a high pharmacist turnover rate, with many pharmacists still in various phases of training.
Case 3
A 10-year-old male with short bowel syndrome secondary to abdominal wall blast injury presented for a routine outpatient visit. Upon review of compounding records, the HPN pharmacist discovered that the solution contained 700 mcg/d copper (23.3 mcg/kg/d) instead of the prescribed amount of 400 mcg/d (13.3 mcg/kg/d). The HPN prescription specified a trace element combination product providing 300 mcg/d copper with instructions to add an additional 100 mcg/d copper for a total of 400 mcg/d. Instead, the home infusion pharmacy provided the correct amount of trace element combination product but added an additional 400 mcg/d copper for a total of 700 mcg/d. This error had been occurring for approximately 1 week. The patient's examination was at baseline. The team deferred additional laboratory studies since the total copper dose provided was still within a normal range for the patient's weight and the duration of exposure was only 7 days. The HPN team contacted the home infusion pharmacy, and a correctly compounded shipment of HPN was delivered shortly thereafter.
Case 4
A 9-month-old former 24-week gestation infant female with short bowel syndrome secondary to necrotizing enterocolitis presented for a routine clinic visit. The HPN pharmacist reviewing her compounding records noted the solution contained 108 mEq/L sodium (7.5 mEq/kg/d) as opposed to the prescribed 65 mEq/L (4.5 mEq/kg/d). The patient had received the incorrect solution for 10 days. At the outpatient appointment, the patient was well appearing, but weight gain was greater than expected. Her serum sodium concentration was normal at 137 mmol/L (normal range, 135-148 mmol/L). Clinicians attributed the excess weight gain to sodium-related fluid retention as opposed to excess calorie provision. The team did not make any adjustments to the HPN prescription until the patient could be reassessed once receiving the solution with the correct amount of sodium. The home infusion pharmacy was contacted regarding the error, and new, corrected HPN bags were compounded. The pharmacy attributed the sodium discrepancy to human error and planned to follow up with a root cause analysis. However, no further follow-up has been documented to date.
Case 5
A 12-month-old, former 35-week gestation male infant with short bowel syndrome secondary to gastroschisis presented for a routine clinic visit. Although the amount of copper added was outside of the typical dose range, the compounding software did not make use of dose-range checking with automatic doserange alerts. The original prescription was not used as the source document when a second pharmacist performed a double-check, and thus the error was missed again. Although the HPN was dispensed several times in subsequent weeks, only the adjusted ingredients were reviewed each time. Because copper was never adjusted, it was never rechecked, and thus the copper dose remained incorrect in the HPN solution for 2 months.
Case 6
A 2-year-old male with short bowel syndrome secondary to a history of malrotation and midgut volvulus was seen for a routine outpatient visit. The pharmacist reviewing the patient's HPN compounding records discovered that the HPN volume and electrolyte concentrations were not compounded as prescribed. The prescription specified a total nutrient admixture (TNA), containing fats in the same bag as the dextrose/amino acid solution, with a total TNA volume of 690 mL (600 mL dextrose/amino acid solution with 90 mL fat solution). However, the TNA was compounded with a total volume of only 600 mL (510 mL dextrose/amino acid solution with 90 mL fat solution). Because the TNA was compounded based on a smaller volume, the final concentration of all electrolytes in the solution was also incorrect. The patient had recently transferred to a new home infusion pharmacy. This new pharmacy was contacted to discuss the error, and the pharmacist at that company reported that the HPN prescription was misinterpreted upon formulation (ie, the ordered dextrose/amino ordered volume of 600 mL was mistakenly thought to be the total TNA volume).
Case 7
A 5-year-old male with short bowel syndrome secondary to a history of necrotizing enterocolitis presented for a routine clinic visit. Upon review of compounding records, the HPN pharmacist discovered that the potassium content and anion balance did not match the prescription. (normal range, 22-30 mmol/L). It was discovered that the home infusion pharmacist had not accounted for the amount of potassium contributed by the potassium phosphate during HPN formulation. This error resulted in the higher total HPN potassium concentration. The anion balance had also been calculated incorrectly upon formulation. Both calculations were done by hand without using compounding software, and no doublecheck was performed. The home infusion pharmacy subsequently prepared a corrected shipment of HPN.
Discussion
For children with severe digestive disorders, HPN and IV hydration are life-saving therapies that many families and caregivers can safely administer at home. 12 They are also complex, high-risk medications associated with errors that can lead to serious patient harm. Errors can occur at any point along the medication use process: prescribing, transcribing, dispensing, administering, and monitoring. 13 The errors reported here occurred in the dispensing phase at the home infusion pharmacy and highlight important points for clinicians involved in the HPN process to be aware of to help identify and prevent errors.
Open communication can help HPN teams to identify knowledge gaps with home infusion pharmacy staff and to avoid errors. In case 1, the IV hydration solution was compounded by a subcontracted pharmacy that had previously demonstrated knowledge gaps and was no longer receiving referrals by this HPN program. Subsequently, our hospital has worked with numerous local and national home infusion pharmacies to create greater transparency, including notification of the team whenever an alternate facility is used to compound a patient's solution. Similarly, HPN pharmacists communicating with the home infusion pharmacy involved in case 2 identified that the pharmacy involved was not using the software available for their ACD. Such software programs have been shown to improve compounding accuracy. 5, 14 Prescribers should communicate uncommon compounding requests clearly and directly to the home infusion pharmacy to prevent confusion. In case 3, the home infusion pharmacy misinterpreted the copper amount ordered on the HPN prescription, resulting in an overdose. This error could potentially have been avoided had the HPN team proactively called and explained to the compounding pharmacy that the copper ordered was an additional 100 mcg added to the 300 mcg for a daily total of 400 mcg copper from all sources. It is well known that backorders of nutrition products needed for PN compounding are frequent 15 and may necessitate substitution of 1 product for another, often on short notice. Home infusion pharmacists should clearly relate any substitutions or omissions back to the prescriber so that HPN teams can put in place any additional clinical monitoring necessary. Because compounding and delivery of HPN to the patient's home are often time sensitive, communications between pharmacies and HPN teams can be especially challenging. However, these opportunities for communication allow clinicians to foster ongoing professional relationships with their colleagues, facilitating exchange of knowledge and enhancing patient care.
After submitting HPN prescription changes, the clinical team should review the compounding records as soon as possible. Reconciliation of each compounded HPN or IV hydration solution prior to infusion would be ideal, such that errors could be detected before they reach the patient. In cases 4 and 5, the errors had been occurring for 10 days and 2 months, respectively, without being noticed. Several obstacles may prevent HPN teams from performing such reconciliation in a timely fashion. It is currently not common practice for the home infusion pharmacy to send compounding records to the prescribers to review for accuracy. Based upon our experience, HPN teams may benefit from proactively requesting compounding records. Pharmacists are in an ideal position to review and interpret HPN compounding records due to their specialized knowledge of different drug products and the effects they may have on the physical and chemical profile of an HPN solution. There are challenges, however, to incorporating a pharmacist into the workflow. One challenge is that few programs have the resources to support a clinical pharmacist for nonbillable activities such as prescription reconciliation. Furthermore, an HPN pharmacist may not always be available to do an immediate review since home infusion compounding may happen on evenings, weekends, or holidays. While reconciliation by a pharmacist may be ideal, other clinicians specialized in nutrition support (eg, dietitians, nurses, nurse practitioners, physicians) could be trained to perform HPN reconciliation. Such training would require a nonpharmacist to become familiar with products and calculations used to compound HPN solutions. Although it may require a good deal of extra effort on the part of both HPN teams and home infusion pharmacies, timely HPN reconciliation can enhance patient safety and improve outcomes.
Standardized prescribing and compounding guidelines would be helpful for both the prescribers and the pharmacies in reducing errors. 6 There is currently no legally mandated standard for prescribing or compounding HPN or IV hydration. As a result, HPN and IV hydration prescriptions are written in widely varying formats, and home infusion pharmacies differ in compounding practices. The lack of standardization can lead to confusion, especially when patients change healthcare settings. 16 Case 6 demonstrated confusion that occurred when a patient transitioned to a new home infusion pharmacy that misinterpreted the volume of the prescribed TNA. The American Society for Parenteral and Enteral Nutrition (ASPEN), American Society of Health-System Pharmacists (ASHP), and Institute for Safe Medication Practices (ISMP) have all published clinical guidelines and safe practice recommendations regarding PN prescribing and compounding, [5] [6] [7] 17, 18 but adherence is voluntary, and not all pharmacists may be aware of these guidelines. ASPEN guidelines provide an example of a standardized pediatric PN order template (Figure 1) . 5 Home infusion pharmacies vary widely in their approaches to compounding, depending on that company's software, equipment, staffing, and other variables. We observed compounding errors resulting from failure to follow 2 specific safety recommendations: utilization of dose-limit warnings (case 5) and independent double-checks (case 7). ACD software may include dose-limit warnings that alert clinicians when a PN ingredient is ordered in an amount outside of the usual dose range and can help to prevent catastrophic dosing errors. However, it should be noted that not all ACD software programs use dose-range checking as part of their safety alerts. 19 Independent double-checks of high-risk medications such as PN are recommended to identify and prevent errors. 20 Such errors demonstrate the need for standardization of HPN prescribing and compounding practices. Limiting variation of these practices can minimize opportunities for misinterpretation and errors and may be especially important during transitions of care. While there is currently no legal mandate, it is crucial for HPN clinicians to follow and encourage best practices and guidelines, as well as share such information with colleagues.
Although this report focuses on errors made by home infusion pharmacies, HPN teams can also be culpable. Prescriptions may not be able to be compounded as ordered by the home infusion pharmacy for a variety of reasons, including product backorders and formulary preferences. In addition, PN stability limitations are quite different between the inpatient setting, in which solutions are compounded and immediately infused, and the homecare setting, in which the solution may not be 
